

## Clotting Disorders

Reference Number: RDF1434-23

Date of Response: 25/04/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Could you please provide answers to the following four questions related to the incidence and treatment of Clotting Disorders?

1. How many patients has your Trust treated (for any medical condition) in the past 3 months with the following drugs:

Drug	RDUH total
Alphanate	0
Alprolix	*<5
BeneFIX	0
HaemateP	0
Idelvion	0
Nuwig	0
Refixia	0
Rixubis	0
Veyvondi	0
Voncento	*<5
Wilate	*<5
Willfact	0

2. How many patients have been treated in the past 3 months with:

- Gene therapy for Haemophilia B ONLY

No patients were treated with Gene Therapy for Haemophilia B

- Desmopressin for Von Willebrand Disease ONLY - \*<5 Please note:

\* We cannot say that these patients were treated specifically for this condition, just that they were prescribed a drug and that they also have been diagnosed with this condition

- Tranexamic Acid for Von Willebrand Disease ONLY - \*<5 Please note:

\* We cannot say that these patients were treated specifically for this condition, just that they were prescribed a drug and that they also have been diagnosed with this condition

\*Section 40 (2) - Less than five <5

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases  $\leq 5$  is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

3. Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment:

- During surgery - No patients were treated with Veyvondi during surgery.
- On demand to treat bleeding episodes – No patients were treated with Veyvondi on demand to treat bleeding episodes.

4. How many patients are registered with your trust for the following diseases:

- Haemophilia B – 13 patients
- Von Willebrand Disease - 70 patients (total of paediatric and adult patients).
- Von Willebrand Disease - paediatric patients (age 17 or under) – 12 patients